Described herein are methods and assays for determining the presence or absence of certain markers useful in informing treatment of one or more subjects with one or more activin inhibitors. In certain aspects the one or more subjects can have cancer. In certain aspects the markers can include INHBA and ACVR2B. In certain aspects one or more subjects can be treated with an activin inhibitor.
